Multiple factors come into play when providers and patients discuss a disease-modifying therapy for multiple sclerosis (MS), explains Patricia K. Coyle, MD, of Stony Brook University Neurosciences Institute.
Transcript
What are some of the considerations that clinicians should take into account when choosing a disease-modifying therapy?
Well, I think there are multiple factors in shared-decision making. I think the principle of early treatment is very key. The principle of shared decision making is very key—you want the patient to be a partner. So you want them to be informed and educated to have a true understanding about MS. And then I think principal factors are, what are individual goals and this would also account for, do they have comorbid conditions, what are their lifestyle expectations? Are they looking at pregnancy as something down the line that is important? So there are individual subject goals. There are MS disease goals. How active is their MS? What sort of prognostic profile does the patient have? Someone who has very active disease, somebody that you're very worried about, [they] look like they're fitting into a poor prognosis. Efficacy of your DMT choice now becomes very important, critically important. And then I think finally, the DMT. And this is the mode of delivery, the safety, the tolerability, the adverse events, the efficacy of the drug, the monitoring that is required. These are kind of the principal factors that are calculated into coming up with the best disease-modifying therapy choice for the individual patient.
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More